Pandora Wealth’s Cyclerion Therapeutics CYCN Stock Holding History

Pandora Wealth’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11	Closed	-$32	–	242
2025 Q2	$32	Buy	+11	New	+$33	﹤0.01%	293

Other funds holding CYCN

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Pandora Wealth's CYCN Position: Q3 2025 in Review

Pandora Wealth sold out of Cyclerion Therapeutics (CYCN) in Q3 2025, closing a stake of 11 shares — an estimated $32 sold.

Pandora Wealth first reported a position in CYCN in Q2 2025 and held it in 1 quarter. The position peaked at $32 in Q2 2025. 17 funds tracked by Wall St. Rank hold CYCN as of Q3 2025.

Pandora Wealth reported no remaining Cyclerion Therapeutics position as of Q3 2025 after selling out during the quarter.
Pandora Wealth sold 11 Cyclerion Therapeutics shares in Q3 2025, an estimated $32.
Pandora Wealth first reported a position in Cyclerion Therapeutics in Q2 2025 and held it in 1 quarter.
Pandora Wealth's Cyclerion Therapeutics position peaked at $32 in Q2 2025.
17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2025.

Based on Pandora Wealth's 13F filing for Q3 2025, filed 3 Nov 2025.